鶹ýӰ

Ozempic Overdoses; Diabetes Supplement Warning; Sen. Sanders Blames Food Industry

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, MedPage Today

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

Poison centers reported a sharp increase in of the diabetes and weight-loss drug semaglutide (Ozempic, Wegovy). (CNN)

Some patients with diabetes for their GLP-1 agonists, a byproduct of insurers tightening the screws on prescribing the class of drugs for weight loss. (Reuters)

A novel, significantly reduced HbA1c and weight (-1.02% and -3.26% placebo-adjusted change with 90 mg, respectively) after 12 weeks in people with type 2 diabetes in a phase IIa trial, announced developer Structure Therapeutics.

Science has crowned GLP-1 agonists as its .

Beware of that claim to treat or even cure diabetes, the FDA warned.

Emergency department visits by jumped more than 50% from 2012 to 2021, CDC data indicated, increasing from 48.6 to 74.9 visits per 1,000 adults.

Ohio lawmakers passed a bill that to transgender youth; Gov. Mike DeWine (R) has not yet indicated whether he will sign it. (WKSU)

launched its revamped diabetes management platform for insulin pump users. (MedTech Dive)

The prevalence of in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) increased from 2016 to 2020, according to a study in Pediatrics.

In an opinion piece, Sen. Bernie Sanders (I-Vt.) for the diabetes epidemic. (USA Today)

This is why are embracing weight-loss drugs. (NPR)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.